Not Signed In - Wyeth And Progenics To Begin Clinical Testing Of A New Formulation Of Oral Methylnaltrexone Based On Phase 2 Findings
Wed, 07 Mar 2007 08:00 AM EST
... Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that Wyeth is beginning clinical testing this month of a new formulation of oral methylnaltrexone for the treatment of opioid-induced constipation. [click link for full article] ...
Related Topics
- Clinical Trials
- HIV Testing
- Faith-based Initiatives
- Community and Faith-Based Initiatives
- Faith-Based and Community Initiatives
- Genetic Testing
- Learning Disorders
- Pharmacology
- Psychopharmacology
- Clinical Laboratory Improvement Amendments
- Bexarotene Oral
- Oral Cancer
- The signs and symptoms related to the central nervous system may be irreversible if treatment is not begun within 6 months of when these symptoms begin.
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Oral Health
- Prenatal Testing
- Clinical Growth Charts
- Cytology
- Stds
email this page
print this page
bookmark this page
feedback on this page
